Free Trial

Two Sigma Advisers LP Has $7.09 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Syndax Pharmaceuticals logo with Medical background

Two Sigma Advisers LP trimmed its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 19.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 535,952 shares of the company's stock after selling 133,400 shares during the period. Two Sigma Advisers LP owned 0.63% of Syndax Pharmaceuticals worth $7,085,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Octagon Capital Advisors LP bought a new stake in Syndax Pharmaceuticals in the fourth quarter worth $11,951,000. Renaissance Technologies LLC bought a new position in shares of Syndax Pharmaceuticals in the 4th quarter valued at approximately $9,002,000. Trexquant Investment LP lifted its holdings in Syndax Pharmaceuticals by 1,309.7% in the 4th quarter. Trexquant Investment LP now owns 471,292 shares of the company's stock worth $6,230,000 after purchasing an additional 437,859 shares during the last quarter. Altium Capital Management LLC acquired a new stake in Syndax Pharmaceuticals in the 4th quarter worth approximately $4,891,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Syndax Pharmaceuticals during the fourth quarter worth approximately $4,734,000.

Syndax Pharmaceuticals Stock Up 1.9%

SNDX traded up $0.19 during trading on Wednesday, reaching $10.12. 1,820,032 shares of the company's stock were exchanged, compared to its average volume of 1,778,865. The company has a market capitalization of $870.80 million, a P/E ratio of -2.79 and a beta of 0.82. The business has a 50 day moving average price of $11.68 and a 200 day moving average price of $13.58. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $8.58 and a fifty-two week high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($1.04) by $0.06. The business had revenue of $20.04 million for the quarter, compared to the consensus estimate of $15.88 million. Syndax Pharmaceuticals's revenue was up 1900.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.85) earnings per share. As a group, research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Syndax Pharmaceuticals to a "sell" rating in a research note on Tuesday, May 6th. Guggenheim restated a "buy" rating and set a $32.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, May 6th. Scotiabank raised their price target on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a research report on Tuesday, May 6th. JPMorgan Chase & Co. raised their target price on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a report on Thursday, March 20th. Finally, HC Wainwright reiterated a "buy" rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $35.91.

View Our Latest Stock Report on Syndax Pharmaceuticals

Syndax Pharmaceuticals Profile

(Free Report)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

Featured Stories

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Should You Invest $1,000 in Syndax Pharmaceuticals Right Now?

Before you consider Syndax Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.

While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines